Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vivatuxin immune targeted brachytherapy with or without microwave ablation for lung cancer
ChiCTR-TRC-10001040Phase 4Completed
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Dec 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 4, open-label trial of iodine-131-chTNT in bronchial carcinoma and non-small cell lung cancer (NSCLC) (3 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoints: Safety, Tumor markers and 2 more. Started Dec 2009; status: completed.
02
Drugs
iodine-131-chTNT
03
Conditions
bronchial carcinomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-10001040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001040.